Cogent Biosciences management says it expects FDA approval of bezuclastinib, with PDUFA dates of November 30th, December 30th and June 29th of 2027. Liver transaminase elevations are described as fluctuating, with no significant clinical sequelae.
COGT · Cogent Biosciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 22%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Cogent's lead drug bezuclacinib has PDUFA dates of November 30 for imatinib-resistant GIST, December 30 for non-advanced systemic mastocytosis, and June 29, 2027 for advanced systemic mastocytosis. The company says it is ready to ship product within two or three days of approval.
Cogent says bezuclacinib is days away from FDA approval, with November 30th set as the first PDUFA date for GIST. Commercial teams are in place, and orders could begin within a day or two of clearance.
Cogent has three bezuclastinib NDAs pending FDA review, with PDUFA target dates November 30, 2026, December 30, 2026 and June 29, 2027. Cash, cash equivalents and marketable securities of $791.1 million were expected to fund operations into late 2028.
Cogent Biosciences reported a $111.4 million 2026 third-quarter net loss and $791.1 million cash. Bezuclastinib FDA decision dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvSM and June 29, 2027 for AdvSM.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COGT
this stock
Cogent Biosciences, Inc.
|
$4.65B | -24.8% | -65.0% | — | 10.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 18
Cogent Biosciences management says it expects FDA approval of bezuclastinib, with PDUFA dates of November 30th, December 30th and June 29th of 2027. Liver transaminase elevations are described as fluctuating, with no significant clinical sequelae.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COGT | -6.5% | -14.4% | -18.5% | -13.9% | -24.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +2.1% | -5.2% | -9.3% | -5.2% | -26.0% |